Pathology of the liver in mucopolysaccharidosis: light and electron microscopic assessment before and after bone marrow transplantation

• Published in: Bone marrow transplantation (Basingstoke) Vol. 10; no. 3; p. 273
• Main Authors: Resnick, J M, Krivit, W, Snover, D C, Kersey, J H, Ramsay, N K, Blazar, B R, Whitley, C B
• Format: Journal Article
• Language: English
• Published: England 01-09-1992
• Subjects: Bone Marrow Transplantation; Child; Child, Preschool; Female; Glycosaminoglycans - metabolism; Humans; Inclusion Bodies - metabolism; Inclusion Bodies - pathology; Infant; Kupffer Cells - metabolism; Kupffer Cells - pathology; Liver - metabolism; Liver - pathology; Lysosomes - metabolism; Lysosomes - pathology; Male; Microscopy, Electron; Mucopolysaccharidoses - metabolism; Mucopolysaccharidoses - pathology; Mucopolysaccharidoses - surgery
• ISSN: 0268-3369

Serial liver biopsies were obtained in 20 patients undergoing bone marrow transplantation (BMT) for mucopolysaccharidosis (MPS). The 13 patients with MPS I, one with MPS II, four with MPS III, and two with MPS VI underwent liver biopsy prior to and from 1 to 37 months after BMT. The amount of accumulated glycosaminoglycan (GAG) was assessed by semiquantitation of Kupffer cell staining with colloidal iron and by counting the number of hepatocellular GAG-containing lysosomes in electron micrographs. Eleven of 13 patients with MPS I achieved engraftment, and 10 of the 11 cleared the Kupffer cells and hepatocytes of GAG by 3 to 19 months post-BMT. Two patients with autologous recovery demonstrated persistent hepatocyte inclusions. The three patients with MPS II and MPS VI engrafted and showed clearance of hepatocyte and Kupffer cell GAG by 7 months after BMT. All four patients with MPS III engrafted. Although the Kupffer cells in these patients were cleared of GAG by 12 months after BMT, hepatocellular inclusions persisted in all four. For MPS I, II and VI, donor engraftment was associated with resolution of lysosomal storage material in donor-derived Kupffer cells and untransplanted hepatocytes, indicative of transcellular metabolic correction. Failure of hepatocyte clearance in one case of MPS I and all patients with MPS III suggested a diminished capacity of the graft-derived enzyme to enter the hepatocyte lysosomes in these patients.